HC Wainwright Has Bullish Outlook for Savara FY2024 Earnings

Savara Inc (NASDAQ:SVRA) – Equities research analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Savara in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.46) per share for the year, up from their previous estimate of ($0.48). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Savara’s Q4 2024 earnings at ($0.11) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.25) EPS and FY2028 earnings at $0.00 EPS.

Other analysts have also issued research reports about the company. Evercore ISI reissued an “in-line” rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a report on Wednesday. JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.17.

Savara Stock Performance

Shares of SVRA opened at $2.98 on Friday. The company has a quick ratio of 11.31, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The stock has a market cap of $511.43 million, a P/E ratio of -6.93 and a beta of 1.02. The business’s 50 day moving average price is $3.88 and its 200-day moving average price is $4.19. Savara has a 52 week low of $2.83 and a 52 week high of $5.70.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11).

Hedge Funds Weigh In On Savara

Several hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its position in Savara by 92.3% during the 1st quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock valued at $366,000 after purchasing an additional 35,269 shares during the period. Swiss National Bank acquired a new stake in shares of Savara in the 1st quarter worth $732,000. ProShare Advisors LLC grew its stake in Savara by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after buying an additional 2,114 shares during the last quarter. Vanguard Group Inc. increased its position in Savara by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock valued at $30,197,000 after buying an additional 148,673 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co purchased a new stake in Savara in the first quarter valued at about $35,000. 87.93% of the stock is currently owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.